Document Type
Article
Publication Title
Cancer Plus
Abstract
Classical Hodgkin lymphoma is a highly curable malignancy, but long-term treatment-related toxicities remain a challenge, especially in young survivors. In recent years, treatment has shifted from traditional doxorubicin, bleomycin, vinblastine, and dacarbazine regimens to novel approaches such as positron emission tomography-guided therapy, brentuximab vedotin-doxorubicin, vinblastine, dacarbazine (AVD), and checkpoint inhibitor combinations such as nivolumab (Nivo)-AVD. This review evaluates these three frontline strategies in terms of efficacy, toxicity, and their potential to personalize treatment and minimize late complications. Drawing from trials such as ECHELON-1, NIVAHL, SWOG S1826, and BREACH, we analyze current evidence, evaluate conflicting data, and propose considerations for tailoring therapy to patient subgroups.
DOI
10.36922/CP025090013
Publication Date
5-28-2025
Keywords
Hodgkin lymphoma, ABVD, Brentuximab vedotin, Nivolumab, PET-adapted therapy, Immunotherapy, Frontline treatment, Toxicity
ISSN
2661-3840
Recommended Citation
Karri V, Reyes C, Dalia S. Optimizing Frontline Therapy for Classical Hodgkin Lymphoma: A Mini-review of PET-directed Chemotherapy, Brentuximab-based Regimens, and Checkpoint Inhibitor Combinations. Cancer Plus. 2025; . doi: 10.36922/CP025090013.
